This month, two growth stocks I like the look of are Ashtead (LSE: AHT) and PureTech Health (LSE: PRTC). Here’s why I’m seriously considering buying some for my holdings if I can.
Ashtead
Ashtead is one of the largest equipment rental firms serving the construction industry. It makes most of its money in North America, which is where my excitement around potential growth comes from (more on that later).
The shares are down 5% over a 12-month period, from 5,580p at this time last year to current levels of 5,284p. However, this past year has been tough due to volatility. Ashtead shares have been on a tremendous run in recent years, climbing 174% over a five-year period.
I reckon continued economic turbulence is Ashtead’s biggest challenge, at least in the short to medium-term. This is because construction and infrastructure projects slow down during uncertainty, like now. This could hurt performance and investor returns.
However, I’m a long-term investor, therefore I’m looking to the future. In the US, a potentially lucrative infrastructure bill passed by the government could see Ashtead and the wider construction industry benefit. With lots of money to be released, Ashtead could see performance and returns boosted nicely.
A dividend yield of 1.5% and the shares looking decent value for money on a price-to-earnings ratio of 15 help my investment case. I’d expect the shares to continue their upward trajectory, more so once volatility cools. Plus, payouts could grow in line with performance. However, it’s worth mentioning dividends aren’t guaranteed.
PureTech Health
PureTech Health is a bio pharma business specialising in therapies and treatments for serious diseases.
Over a 12-month period, the shares are down 24%, from 246p at this time last year to current levels of 185p. However, it’s worth mentioning that they did spike 49% in December due to some excellent clinical results and positive developments.
In December, the business reported exciting developments in three key areas of its efforts. These were its pulmonary disease treatment, dubbed LYT-100. Next was its central nervous system area, labelled LYT-320. Finally, there were developments in its focus on oncology, known as LYT-200. This helped the shares soar.
In addition to this, Bristol Myers Squibb, a larger bio pharma firm, snapped up PureTech-founded Karuna Therapeutics for a mammoth $14bn. I reckon this deal is a sign that PureTech is making positive waves and breakthroughs in the industry.
The natural risk for PureTech shares is that clinical trials and treatment development don’t bear fruit or aren’t viable. This could have a disastrous impact on the business and shares.
However, I must note that the business looks in good financial health to continue its aims. Its last update mentioned $320m of cash on its balance sheet. This could help support growth aspirations.
Of the two stocks, I consider PureTech to be a tad riskier, but there’s still some exciting potential, if you ask me.
The post 2 impressive growth stocks I’ve got my eye on in February appeared first on The Motley Fool UK.
Should you buy Ashtead Group Plc shares today?
Before you decide, please take a moment to review this first.
Because my colleague Mark Rogers – The Motley Fool UK’s Director of Investing – has released this special report.
It’s called ‘5 Stocks for Trying to Build Wealth After 50’.
And it’s yours, free.
Of course, the decade ahead looks hazardous. What with inflation recently hitting 40-year highs, a ‘cost of living crisis’ and threat of a new Cold War, knowing where to invest has never been trickier.
And yet, despite the UK stock market recently hitting a new all-time high, Mark and his team think many shares still trade at a substantial discount, offering savvy investors plenty of potential opportunities to strike.
That’s why now could be an ideal time to secure this valuable investment research.
Mark’s ‘Foolish’ analysts have scoured the markets low and high.
This special report reveals 5 of his favourite long-term ‘Buys’.
Please, don’t make any big decisions before seeing them.
Claim your free copy now
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#FFFFFF”, ‘color’, ‘#FFFFFF’);
})()
More reading
Brokers just raised their price targets on these top FTSE growth stocks
Up nearly 6,000% since 2010, is this one of the best stocks to buy?
2 FTSE 100 shares I’d buy to try and become a Stocks & Shares ISA millionaire!
Looking for the FTSE’s greatest value stocks? Here are 2 that I love!
Sumayya Mansoor has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
